This Listing of Claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1. (currently amended): Substituted pyrazoline compounds of formula I,

wherein

R¹ represents hydrogen or a linear or branched C_{1.4}-alkyl group,

 R^2 , R^3 and R^4 independently of each other represent hydrogen, a linear or branched C_{1-6} -alkyl group, a linear or branched C_{1-6} -alkoxy group, a halogen atom, CH_2F , CHF_2 , CF_3 , CN, OH, NO_2 , $-(C=O)-R^8$, SH, SR^8 , SOR^8 , SO_2R^8 , NH_2 , NHR^8 , NR^8R^9 , $-(C=O)-NH_2$, $-(C=O)-NHR^8$ or $-(C=O)-NR^8R^9$ whereby R^8 and R^9 for each substituent independently represent linear or branched C_{1-6} alkyl,

 R^5 and R^6 independently of each other represent a linear or branched C_{1-6} alkyl group, a linear or branched C_{1-6} -alkoxy group, a halogen atom, CH_2F , CHF_2 , CF_3 , CN, OH, NO_2 , $-(C=O)-R^{10}$, SH, SR^{10} , SOR^{10} , NH_2 , NHR^{10} , $NR^{10}R^{11}$, $-(C=O)-NH_2$, $-(C=O)-NHR^{10}$ or $-(C=O)-NR^{10}R^{11}$, whereby R^{10} and optionally R^{11} for each substituent independently represent linear or branched C_{1-6} alkyl;

 R^7 represents hydrogen, a linear or branched C_{1-6} -alkyl group, a linear or branched C_{1-6} -alkoxy group, a halogen atom, CH_2F , CHF_2 , CF_3 , CN, OH, NO_2 , $-(C=O)-R^{10}$, SH, SR^{10} , SOR^{10} , NH_2 , NHR^{10} , $NR^{10}R^{11}$ $-(C=O)-NH_2$, $-(C=O)NHR^{10}$ or $-(C=O)-NR^{10}R^{11}$, whereby R^{10} and optionally

 R^{11} for each substituent independently represent linear or branched C_{1-6} alkyl;

with the proviso that

if R^1 and R^7 are H and R^5 and R^6 both represent Cl in the 3- and 4-position of the phenyl ring neither of R^2 , R^3 and R^4 may represent F in the 4-position of the phenyl ring if the other two of R^2 , R^3 and R^4 both represent H;

optionally in a form of one of its stereoisomers or a racemate or in a form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof.

- 2. (original): Compounds according to claim 1, characterized in that at least one of R², R³ or R⁴ represents hydrogen, while at least one of R², R³ or R⁴ is different from hydrogen.
- 3. (previously presented): Compounds according to claim 1, characterized in that R⁷ represents hydrogen.
- 4. (previously presented): Compounds according to claim 1, characterized in that R², R³ and R⁴ independently of each other represent hydrogen, a linear or branched C₁₋₆-alkyl group, a halogen atom, or CF₃.
- 5. (currently amended): Compounds according to claim 1, characterized in that R⁵ and R⁶ independently of each other represent-a-linear or branched C₁₋₆-alkyl group, a halogen atom, or CF₃.
- 6. (previously presented): Compounds according to claim 1, characterized in that R² represents a chlorine atom in the 4-position of the phenyl ring, while R³ and R⁴ represent hydrogen.

- 7. (previously presented): Compounds according to claim 1, characterized in that R⁵ and R⁶ each represent chlorine atoms in the 2- and 4-position of the phenyl ring, while R⁷ represents hydrogen.
- 8. (previously presented): Compounds according to claim 1, characterized in that R¹ represents hydrogen, methyl or ethyl.
- 9. (currently amended): Compounds of formula II according to claim 1

wherein

R¹ represents hydrogen or a linear or branched C₁₋₄-alkyl group,

 R^{12} or R^{13} independently of each other represent a linear or branched C_{1-6} -alkyl group, a linear or branched C_{1-6} -alkoxy group, a halogen atom, CH_2F , CHF_2 , CF_3 , CN, OH, NO_2 , SH, NH_2 , hydrogen, methyl, ethyl, F, Cl, Br or CF_3 ,

 R^{14} or R^{15} independently of each other represent-a linear or branched C_{1-6} -alkyl group, a linear or branched C_{1-6} -alkoxy group, a halogen atom, CH_2F , CHF_2 , CF_3 , CN, OH, NO_2 , SH, NH_2 , methyl, ethyl, F, Cl, Br or CF_3 ,

optionally in a form of one of its stereoisomers or a racemate or in a form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof.

- 10. (previously presented): Compounds according to claim 9 characterized in that R¹² and R¹³ independently of each other represent hydrogen, a linear or branched C₁₋₆-alkyl group, a halogen atom, or CF₃.
- 11. (currently amended): Compounds according to claim 9, characterized in that R¹⁴ and R¹⁵ independently of each other represent-a linear or branched C₁₋₆-alkyl group, a halogen atom, or CF₃.
- 12. (previously presented): Compounds according to claim 9, characterized in that R¹³ represents Cl and R¹² represents hydrogen.
- 13. (previously presented): Compounds according to claim 9, characterized in that R¹⁴ and R¹⁵ each represent Cl.
- 14. (previously presented): Compounds according to claim 9, characterized in that R¹ represents hydrogen, methyl or ethyl.
- 15. (previously presented): A compound according to claim 1 which is: 5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-carboxylic acid, optionally in the form of a corresponding N-oxide, a corresponding salt.

Claim 16-39 (canceled)

40. (previously presented): Process for the manufacture of substituted pyrazoline compounds of formula I or II, wherein R¹ is hydrogen, according to claim 1, characterized in that at least one benzaldehyde compound of formula III

(III)

wherein R², R³ and R⁴ have the meaning according to claim 1, is reacted with a pyruvate compound of formula (IV)

wherein G represents an OR group with R being a branched or unbranched C_{1-6} alkyl radical or G represents an O^-K group with K being a cation, to yield a compound of formula (V)

which is optionally isolated or optionally purified, and which is reacted with an optionally substituted phenyl hydrazine of formula (VI)

or a corresponding salt thereof, wherein R⁵, R⁶ and R⁷ have the meaning according to claim 1, under inert atmosphere, to yield a compound of formula (VII)

wherein R^2 , R^3 , R^4 , R^5 , R^6 and R^7 have the meaning as given above, which is optionally isolated or optionally purified, and optionally esterified to an alkyl-ester if in the substituted pyrazoline compound of formula I according to claim 1 R^1 is a linear or branched C_{1-4} -alkyl group.

41. (currently amended): Medicament Composition comprising at least one substituted pyrazoline compound of formula I or II according to claim 1, and optionally one or more pharmaceutically acceptable excipients.

Claims 42-86 (canceled)